Therapeutic effect of PD-1 immunosuppressive agents in non-small cell lung cancer patients with different CY 211 expression levels
Objective To explore the therapeutic effect of programmed cell death protein 1(PD-1)immunosuppressive agents in patients with non-small cell lung cancer(NSCLC)with different expression levels of cytokeratin 19 fragment antigen 21-1(CYFRA 21-1).Methods One hundred patients with NSCLC who received treatment in Tianchang Hospital of Traditional Chinese Medicine from May 2022 to May 2023 were enrolled.With 3.3ng/mL as the critical value,and CYFRA 21-1≥ 3.3ng/mL was selected as the high expression group(n=45)and CYFRA 21-1＜3.3ng/mL as the low expression group(n=55),and all the included patients were treated with PD-1 immunosuppressive agents.The changes in lung function indicators,T lymphocyte subsets,inflammatory factors,treatment-emergent adverse events(TEAEs),and clinical efficacy were included as comparisons between the two groups.Results After treatment,the interferon-gamma(IFN-gamma)levels in the both groups were decreased,the first second forced expiratory volume/forced vital capacity(FEV1/FVC)ratio,forced expiratory volume at 1s to predicted value ratio(FEV1％pred),maximum ventilation volume(MVV),CD4+/CD8+,CD3+,CD4+,interleukin-10(IL-10),and interleukin-6(IL-6)levels were increased.The low expression group showed better improvement in the high expression group in the above indexes(P＜0.01).There was no statistical difference in TEAEs between the two groups(P＞0.05).The disease control rate(DCR)and objective response rate(ORR)were significantly higher in the low expression group than the high expression group(P＜0.05).Conclusion PD-1 immunosuppressive agent treatment in patients with NSCLC has obvious results,especially the patients with low CYFRA 21-1 expression,which can help improve the T lymphatic subset and inflammatory factors,improve lung function,reduce TEAEs,and promote the recovery of patients'disease.
non-small cell lung cancerprogrammed cell death protein 1(PD-1)immunosuppressive agentscytokeratin 19 fragment antigen 21-1(CYFRA 21-1)lung function
万方数据
维普
